AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11043842
Drug: Sodium clodronate
RxNorm normalized name: Sodium clodronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium clodronate 1600 mg daily p.o. (arm A)
Trial: 1735269
Drug: Allergen (Ag)
RxNorm normalized name: catfish allergenic extract
DrugBank: Diphenylpyraline (DB01146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allergen (Ag) inhalation
Trial: 18622283
Drug: Reduced TAC
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced TAC (target trough level 3.0‐5.9 ng/mL)
Trial: 18622283
Drug: Standard TAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard TAC (target trough level 6.0‐8.9 ng/mL)
Trial: 11833837
Drug: Glyburide 15
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide 15 mg/d
Trial: 7718549
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (CaCO3 tablet, 300 mg Ca)
Trial: 15068414
Drug: Sucralfate (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (3 g/day)
Trial: 2202200
Drug: Sulglycotide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulglycotide (600 mg/day)
Trial: 31378665
Drug: Metabolomic profile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolomic profile based on fatty acid metabolism and γ‐glutamyl amino acids
Trial: 26994089
Drug: Ritonavir-boosted lopinavir
RxNorm normalized name: lopinavir / ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir-boosted lopinavir (400/100 mg) with tenofovir disoproxil/emtricitabine (245/200 mg)
Trial: 26994089
Drug: Raltegravir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir (400 mg) with tenofovir disoproxil/emtricitabine (245/200 mg)
Trial: 29091217
Drug: Ritonavir-boosted lopinavir
RxNorm normalized name: lopinavir / ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir-boosted lopinavir (400/100 mg)
Trial: 26994089
Drug: Raltegravir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir (400 mg)
Trial: 25069759
Drug: IFN α‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN α‐2b therapy for ET patients with JAK2V617F(+).
Trial: 25069759
Drug: IFN α‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN α‐2b therapy for PV patients with JAK2V617F(+).
Trial: 25069759
Drug: IFN α‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN α‐2b therapy for MPDs patients.
Trial: 25069759
Drug: IFN α‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN α‐2b therapy.
Trial: 22140200
Drug: Immediate group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate group (2 hours of inpatient physical and occupational therapy focusing on coordination, balance, and ADLs for 4 weeks)
Trial: 17934240
Drug: Royal jelly
RxNorm normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Royal jelly (RJ) supplementation at 6 g per day for 4 weeks
Trial: 7615227
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg per OS three times during the day before the procedure and one 10‐mg dose on the morning of the procedure)
Trial: 2116160
Drug: Atenolol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (4 mg i.v.)
Trial: 2116160
Drug: Buccal nitroglycerin
RxNorm normalized name: nitroglycerin Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal nitroglycerin (5 mg)
Trial: 31356561
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 480 mg/min (group A)
Trial: 31356561
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 240 mg/min (group B)
Trial: 31356561
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 120 mg/min (group C)
Trial: 26062881
Drug: Dual treatment
RxNorm normalized name: Meradimate/Octinoxate/Titanium Dioxide Topical application Lotion [PURPOSE DUAL TREATMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual treatment with atazanavir (300 mg once daily) and ritonavir (100 mg once daily) plus lamivudine (300 mg once daily)
Trial: 26062881
Drug: Triple treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple treatment with atazanavir (300 mg once daily) and ritonavir (100 mg once daily) plus two nucleos(t)ide reverse transcriptase inhibitors
Trial: 26062880
Drug: Triple treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple treatment
Trial: 16415894
Drug: ATG (Thymoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG (Thymoglobulin 2 mg/kg x 3 days)
Trial: 16415894
Drug: Campath (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campath (30 mg x 3 days subcutaneously)
Trial: 16415894
Drug: Campath (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campath (30 mg once)
Trial: 11369502
Drug: alpha-tocopherol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-tocopherol (400 IU dL-alpha-tocopherol daily)
Trial: 10717770
Drug: Natural light/dark
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural light/dark cycle (L/Dc) exposure through windows
Trial: 20697941
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Xiaozheng Zhitong Paste (XZP) in addition to basic therapy (3L analgesia)
Trial: 20697941
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy (3L analgesia) without XZP
Trial: 20697941
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of XZP
Trial: 15787815
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate 50 mg daily or 100 mg for 10 days per month if premenopausal
Trial: 15787815
Drug: Oral antiandrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antiandrogens (combined results of spironolactone and cyproterone acetate)
Trial: 15787815
Drug: Oral antiandrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antiandrogens
Trial: 11994342
Drug: ARG plus
RxNorm normalized name: Arg
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ARG plus L-DOPA test
Trial: 11994342
Drug: L-DOPA test
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-DOPA test
Trial: 2653414
Drug: Progestational agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestational agents
Trial: 24811578
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg paroxetine every day for 1 month
Trial: 24811578
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tadalafil on demand 2 hours before intercourse
Trial: 15290412
Drug: Granisetron 1
RxNorm normalized name: granisetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 1 mg and 3 mg
Trial: 11742045
Drug: Supportive‐expressive group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive‐expressive group therapy
Trial: 8493295
Drug: Electroencephalographic (EEG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroencephalographic (EEG) sleep assessments after successful treatment
Trial: 26492477
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg midodrine hydrochloride
Trial: 21436319
Drug: Corticosteroids +
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids + antifungal
Trial: 21436319
Drug: Antifungal only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal only
Trial: 18297267
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus injections (IB) of meropenem 1 g every 12 h
Trial: 18297267
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of meropenem 0.5 g loading dose followed by 2 g over 24 h
Trial: 14623657
Drug: Active glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active glyceryl trinitrate transdermal patch
Trial: 1642936
Drug: ketorolac trometamol
RxNorm normalized name: Ketorolac trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac trometamol 10 mg administered 4‐hourly by intermittent i.m. injection or by continuous i.m. infusion
Trial: 6829920
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (controlled ventilation with N2O‐O2, intravenous fentanyl and pancuronium bromide; narcotic analgesics intramuscularly on demand postoperatively)
Trial: 29676480
Drug: Medication compliance
RxNorm normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medication compliance and insight into schizophrenia
Trial: 29676480
Drug: Expert witness
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expert witness explanation regarding medication compliance and insight
Trial: 23771784
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin algorithm
Trial: 18036719
Drug: Dutasteride 0.5mg
RxNorm normalized name: DUTASTERIDE 0.5MG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5mg daily
Trial: 16650232
Drug: Albendazole single
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole single dose (400 mg)
Trial: 16650232
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg for 3 days)
Trial: 16650232
Drug: 1% permethrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% permethrin + albendazole single dose (400 mg)
Trial: 16650232
Drug: 1% permethrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% permethrin + albendazole (400 mg for 3 days)
Trial: 10961748
Drug: Senna compound
RxNorm normalized name: senna compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senna compound
Trial: 9124864
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of pefloxacin twice daily for 5 days (group A)
Trial: 9124864
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of pefloxacin twice daily for 7 days (group B)
Trial: 29237339
Drug: Rhythm-and-music-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm-and-music-based therapy (R-MT), n=37
Trial: 29237339
Drug: Horse-riding therapy
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horse-riding therapy (H-RT), n=37
Trial: 29237339
Drug: Rhythm-and-music-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm-and-music-based therapy (R-MT) and Horse-riding therapy (H-RT)
Trial: 22784835
Drug: 52 mg
RxNorm normalized name: papain 52 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 52 mg hydrated implant
Trial: 22784835
Drug: 84 mg
RxNorm normalized name: silymarin 84 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 84 mg hydrated implant
Trial: 22784835
Drug: 84 mg
RxNorm normalized name: silymarin 84 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 84 mg nonhydrated implant
Trial: 21167080
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment with sarpogrelate (300 mg/day)
Trial: 21167080
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment without sarpogrelate
Trial: 17435520
Drug: Corneal Refractive
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corneal Refractive Therapy (CRTH) lens (Dk = 100)
Trial: 15616299
Drug: Tigecycline single-dose
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tigecycline single-dose (12.5 to 300 mg)
Trial: 15616299
Drug: Tigecycline multiple-dose
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tigecycline multiple-dose (25 to 100 mg every 12 h)
Trial: 15616299
Drug: Tigecycline variable
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tigecycline variable volume and infusion rate (100 mg loading dose, followed by 50 mg every 12 h for 5 days)
Trial: 11122886
Drug: High-dose pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pulse therapy with 13-cis-retinoic acid (13-cis-RA) after intensive chemoradiotherapy
Trial: 17173588
Drug: Erbium:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erbium:YAG laser plus topical 5-flurouracil
Trial: 15248876
Drug: Both IMZ
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both IMZ and Brånemark implants
Trial: 9114824
Drug: Experimental agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental agents (other interferons, methotrexate, linomide, monoclonal antibodies, T‐cell receptor peptides, 2‐chlorodeoxyadenosine)
Trial: 18221251
Drug: Fructose (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (40 g, 12% solution)
Trial: 18221251
Drug: High fructose
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fructose corn syrup (HFCS)
Trial: 20877359
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with CA 19-9 monitoring
Trial: 9935257
Drug: Alatrofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alatrofloxacin (200 mg intravenous)
Trial: 9935257
Drug: Cefotetan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan (2 g intravenous)
Trial: 8148278
Drug: Doxycycline 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 0.1 g twice daily
Trial: 8148278
Drug: Lymecycline 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymecycline 0.6 g twice daily
Trial: 3130927
Drug: Chloroquine phosphate
RxNorm normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine phosphate 500 mg weekly with proguanil hydrochloride 200 mg daily
Trial: 3130927
Drug: Chloroquine 500
RxNorm normalized name: chloroquine 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 500 mg weekly with sulfadoxine 500 mg‐pyrimethamine 25 mg weekly
Trial: 24633823
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus unfractionated heparin
Trial: 20975054
Drug: Extended-release melatonin
RxNorm normalized name: melatonin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release melatonin (Circadin®) at a dose of 2 mg 1 hour before bedtime for 8 weeks
Trial: 19006470
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g of omega-3-acid ethyl esters (P-OM3) with 80 mg atorvastatin daily
Trial: 12548212
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (20 microg every 2 hours, increased to 40 microg depending on uterine contractions)
Trial: 12548212
Drug: Vaginal dinoprostone
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal dinoprostone (2 mg twice, 6 hours apart)
Trial: 8561069
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (2.5 g/d for 2 months)
Trial: 1652597
Drug: Combined estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined estrogen and progestin (conjugated equine estrogens, 2.5 mg/day and medroxyprogesterone acetate, 60 mg/day)
Trial: 1652597
Drug: Estrogen (conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen (conjugated equine estrogens, 2.5 mg/day)
Trial: 1652597
Drug: Progestin (medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestin (medroxyprogesterone acetate, 60 mg/day)
Trial: 22922768
Drug: Broncho‐Vaxom (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broncho‐Vaxom (7 mg daily for the first 10 days of each month for 3 months)
Trial: 22922768
Drug: Corticosteroid and/or
RxNorm normalized name: Corticosteroid and/or corticosteroid derivative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid and/or immunosuppressive therapy (control group)
Trial: 16394405
Drug: Formulation C
RxNorm normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation C (mometasone furoate)
Trial: 16394405
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A (mometasone furoate)
Trial: 16394405
Drug: Formulation D
RxNorm normalized name: Complete Formulation D3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation D (mometasone furoate)
Trial: 10767241
Drug: Oral appliances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral appliances with 2-mm mandibular advancement
Trial: 10767241
Drug: Oral appliances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral appliances with 4-mm mandibular advancement
Trial: 10767241
Drug: Oral appliances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral appliances with 6-mm mandibular advancement
Trial: 10767241
Drug: Oral appliances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral appliances (all advancements)
Trial: 9130733
Drug: GnRH-a plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH-a plus EE-CPA pill
Trial: 9130733
Drug: EE-CPA pill
RxNorm normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EE-CPA pill alone
Trial: 8452318
Drug: Intranasal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal budesonide as dry powder (400 micrograms daily, one inhalation/nostril/day)
Trial: 8452318
Drug: Intranasal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal budesonide as aerosol (400 micrograms daily, two puffs/nostril/day)
Trial: 8452318
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not applicable, both groups received active treatment)
Trial: 26795282
Drug: efavirenz, maraviroc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efavirenz, maraviroc or maraviroc+raltegravir with fixed-dose tenofovir disoproxil fumarate/emtricitabine
Trial: 24532547
Drug: Nebivolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (5 mg once daily for 8 days)
Trial: 24532547
Drug: Placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once daily for 8 days)
Trial: 278459
Drug: Atropine 0.0075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.0075 mg/kg
Trial: 8109230
Drug: Atropine 0.02
RxNorm normalized name: ATROPINE 0.025/DIFENOXIN 1MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.02 mg/kg
Trial: 278459
Drug: Atropine 0.01
RxNorm normalized name: atropine 0.0194 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.01 mg/kg to 0.02 mg/kg
Trial: 29938420
Drug: Intramuscular 17‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 17‐alpha hydroxyprogesterone
Trial: 29938420
Drug: Intramuscular Neurobion
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Neurobion
Trial: 22717414
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer lactate solution at 240 mL per hour (group 4)
Trial: 22717414
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous hydration (group 1)
Trial: 22717414
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer lactate solution (any group)
Trial: 20393152
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance (homeostasis model assessment index)
Trial: 18499399
Drug: ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ferrous sulfate (200 mg twice a day, corresponding to 80 mg of elemental iron)
Trial: 18499399
Drug: ferrous glycinate
RxNorm normalized name: Ferrous cysteine glycinate
DrugBank: Ferrous cysteine glycinate (DB11197)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ferrous glycinate chelate (250 mg/d, corresponding to 50 mg of elemental iron)
Trial: 15925562
Drug: Celacade (immune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celacade (immune modulation therapy)